Type of Document Dissertation Author Myers, Matthew V URN etd-01242012-122721 Title Proteomic Signatures of Epidermal Growth Factor Receptor Signaling Degree PhD Department Biochemistry Advisory Committee
Advisor Name Title Daniel C. Liebler Committee Chair Carlos Arteaga Committee Member Graham Carpenter Committee Member Jennifer Pietenpol Committee Member Robert Coffey Committee Member Keywords
- mass spectrometry
Date of Defense 2011-12-19 Availability unrestricted AbstractAnalysis of cellular signaling networks typically involves targeted
measurements of phosphorylated protein intermediates. However,
phosphoproteomic analyses usually require affinity enrichment of
phosphopeptides and can be complicated by artifactual changes in
phosphorylation caused by uncontrolled preanalytical variables, particularly in
the analysis of tissue specimens. I hypothesized that changes in protein
expression, which are more stable and easily analyzed, could reflect network
stimulation and inhibition. This approach was employed to analyze stimulation
and inhibition of the epidermal growth factor receptor (EGFR) by EGF and
selective EGFR inhibitors. Shotgun analysis of proteomes from proliferating
A431 cells, EGF-stimulated cells and cells co-treated with the EGFR inhibitors
cetuximab or gefitinib identified groups of differentially expressed proteins.
Comparisons of these protein groups identified 13 proteins whose EGF-induced
expression changes were reversed by both EGFR inhibitors. Targeted multiple-
reaction-monitoring (MRM) analysis verified differential expression of 12 of
these proteins, which comprise a candidate EGFR inhibition signature. I then
tested these 12 proteins by MRM analysis in 3 other models: 1) a comparison of
DiFi (EGFR inhibitor-sensitive) and HCT116 (EGFR-insensitive) cell lines, 2) in
formalin-fixed, paraffin-embedded (FFPE) mouse xenograft DiFi and HCT116
tumors, and 3) in tissue biopsies from a patient with the gastric
hyperproliferative disorder Ménétrier’s disease, who was treated with cetuximab.
Of the proteins in the candidate signature, a core group, including c-Jun,
jagged-1, and claudin 4 were decreased by EGFR inhibitors in all three models.
Although the goal of these studies was not to validate a clinically-useful EGFR
inhibition signature, the results confirm the hypothesis and outline a
prototypical approach to derive and test protein expression signatures for drug
action on signaling networks.
A secondary goal of this research was to apply a new method to quantify
protein modification changes to EGFR using internal reference peptides (IRP).
The major focus of this work was to assess the performance of this newly
developed MS-based quantitation method to detect phosphorylation changes on
EGFR by comparing the performance characteristics to stable isotope dilution
(SID) methods. Initial studies are presented along with suggestions for future
studies using overall findings in this dissertation.
Filename Size Approximate Download Time (Hours:Minutes:Seconds)
28.8 Modem 56K Modem ISDN (64 Kb) ISDN (128 Kb) Higher-speed Access MVMyers_dissertation.pdf 8.34 Mb 00:38:36 00:19:51 00:17:22 00:08:41 00:00:44